v3.26.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Jun. 30, 2026
Dec. 31, 2025
Current assets:    
Cash and cash equivalents $ 3,431,000 $ 3,006,000
Prepaid expenses and other current assets 562,000 392,000
Total current assets 3,993,000 3,398,000
Property and equipment, net 123,000 162,000
Operating lease right-of-use asset 931,000 1,052,000
Other assets 863,000 948,000
Total assets 5,910,000 5,560,000
Current liabilities:    
Accounts payable 2,697,000 942,000
Accrued clinical trials expenses 933,000 1,426,000
Accrued compensation 1,897,000 2,872,000
Other accrued expenses 1,815,000 1,657,000
Total current liabilities 7,342,000 6,897,000
Convertible notes at fair value, including related party amount of $1,755 and $34,600 at June 30, 2026 and December 31, 2025, respectively 1,755,000 34,600,000
Operating lease liability 757,000 893,000
Derivative liability   14,879,000
Warrant liabilities 11,367,000 3,276,000
Contingent consideration liability 27,000 42,000
Other liabilities 23,000  
Total liabilities 21,271,000 60,587,000
Commitments and contingencies (Note 7)
Stockholders' Deficit:    
Class A common stock, $0.0001 par value; 1,040,000,000 and 500,000,000 shares authorized at June 30, 2026 and December 31, 2025, and 26,307,211 and 12,105,902 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively 10,000 9,000
Additional paid-in capital 468,396,000 415,783,000
Accumulated deficit (483,767,000) (470,819,000)
Total stockholders' deficit (15,361,000) (55,027,000)
Total liabilities and stockholders' deficit $ 5,910,000 $ 5,560,000